Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
Intrinsic Value
Jiangsu Nhwa Pharmaceutical Co., Ltd. engages in the pharmaceutical production, research and development, and sales. [ Read More ]
The intrinsic value of one
Jiangsu Nhwa Pharmaceutical Co Ltd
stock under the Base Case scenario is
31.1
CNY.
Compared to the current market price of 24.15 CNY,
Jiangsu Nhwa Pharmaceutical Co Ltd
is
Undervalued by 22%.
Jiangsu Nhwa Pharmaceutical Co Ltd's market capitalization is 24.3B CNY.
Jiangsu Nhwa Pharmaceutical Co Ltd stock price is 24.15 CNY.
Jiangsu Nhwa Pharmaceutical Co Ltd stock price (24.15 CNY) is 22% less than its Intrinsic Value (31.1 CNY).
Jiangsu Nhwa Pharmaceutical Co Ltd stock price (24.15 CNY) is 21% less than its DCF Value (30.45 CNY). Open DCF Valuation
Jiangsu Nhwa Pharmaceutical Co Ltd stock price (24.15 CNY) is 24% less than its Relative Value (31.76 CNY). Open Relative Valuation
Jiangsu Nhwa Pharmaceutical Co Ltd has upside potential of 37% compared to the average analyst price target.
Open Wall St Estimates
Jiangsu Nhwa Pharmaceutical Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 19% to 17%.
Jiangsu Nhwa Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 32% to 28%.
Jiangsu Nhwa Pharmaceutical Co Ltd's Revenue has grown by 17% over the past 12 months.
Jiangsu Nhwa Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 17%.
Jiangsu Nhwa Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Jiangsu Nhwa Pharmaceutical Co Ltd's Revenue has been growing by 14% per year for the last 3 years.
Jiangsu Nhwa Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Jiangsu Nhwa Pharmaceutical Co Ltd's Revenue is forecast to grow at a rate of 20% per year over the next 3 years.
Jiangsu Nhwa Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 28%.
Jiangsu Nhwa Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 19%. The company is efficient at transforming stockholders' equity into net income.
Jiangsu Nhwa Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Jiangsu Nhwa Pharmaceutical Co Ltd has very high three-year average ROIC (Return on Invested Capital): 32%. The company is very efficient at using invested capital to generate operating income.
Jiangsu Nhwa Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Jiangsu Nhwa Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.03.
Jiangsu Nhwa Pharmaceutical Co Ltd's short-term assets (5B CNY) exceed its short-term liabilties (814m CNY).
Jiangsu Nhwa Pharmaceutical Co Ltd's long-term assets (7B CNY) exceed its long-term liabilties (894m CNY).
Jiangsu Nhwa Pharmaceutical Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (3B CNY) than debt (173m CNY).
Jiangsu Nhwa Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 20.74.
Valuation Backtest
Jiangsu Nhwa Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Jiangsu Nhwa Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Jiangsu Nhwa Pharmaceutical Co Ltd
Balance Sheet Decomposition
Jiangsu Nhwa Pharmaceutical Co Ltd
| Current Assets | 5.3B |
| Cash & Short-Term Investments | 3.3B |
| Receivables | 1.1B |
| Other Current Assets | 814.6m |
| Non-Current Assets | 2.1B |
| Long-Term Investments | 157.3m |
| PP&E | 1.5B |
| Intangibles | 276.2m |
| Other Non-Current Assets | 100.7m |
| Current Liabilities | 814m |
| Accounts Payable | 216.3m |
| Accrued Liabilities | 298.3m |
| Short-Term Debt | 137m |
| Other Current Liabilities | 162.5m |
| Non-Current Liabilities | 80m |
| Long-Term Debt | 35.8m |
| Other Non-Current Liabilities | 44.2m |
Earnings Waterfall
Jiangsu Nhwa Pharmaceutical Co Ltd
|
Revenue
|
5B
CNY
|
|
Cost of Revenue
|
-1.4B
CNY
|
|
Gross Profit
|
3.6B
CNY
|
|
Operating Expenses
|
-2.5B
CNY
|
|
Operating Income
|
1.1B
CNY
|
|
Other Expenses
|
-74.2m
CNY
|
|
Net Income
|
1B
CNY
|
Free Cash Flow Analysis
Jiangsu Nhwa Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
Jiangsu Nhwa Pharmaceutical Co Ltd's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
Score
Jiangsu Nhwa Pharmaceutical Co Ltd's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Jiangsu Nhwa Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Jiangsu Nhwa Pharmaceutical Co Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Jiangsu Nhwa Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Jiangsu Nhwa Pharmaceutical Co Ltd
is 33.04 CNY
with a low forecast of 28.28 CNY and a high forecast of 38.86 CNY.
Shareholder Return
Price
Jiangsu Nhwa Pharmaceutical Co Ltd
| Average Annual Return | 25.18% |
| Standard Deviation of Annual Returns | 29.76% |
| Max Drawdown | -32% |
| Market Capitalization | 24.3B CNY |
| Shares Outstanding | 1 012 310 900 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Jiangsu Nhwa Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Jiangsu Nhwa Pharmaceutical Co., Ltd. engages in the pharmaceutical production, research and development, and sales. The company is headquartered in Xuzhou, Jiangsu and currently employs 4,732 full-time employees. The company went IPO on 2008-07-23. The firm offers its pharmaceutical products under four categories, which consist of anesthetic medicines, including midazolam injections and etomidate fat emulsion pharmaceutical preparations injections; psychiatric medicines, including risperidone tablets and others; neurological medicines, including gabapentin capsules and others; bulk drugs, including fenofibrate and miconazole nitrate. The firm is also engaged in the pharmaceuticals trading business. Through its subsidiaries, the Company is also engaged in the Internet medical businesses. The firm distributes its products within domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Jiangsu Nhwa Pharmaceutical Co Ltd
stock under the Base Case scenario is
31.1
CNY.
Compared to the current market price of 24.15 CNY,
Jiangsu Nhwa Pharmaceutical Co Ltd
is
Undervalued by 22%.
You don't have any saved screeners yet
